Apr 18 2022

Halberd Eliminates E. coli in 20 Minutes vs. 7-10 Days with Conventional Antibiotics

By |2022-04-17T19:16:30-04:00April 18th, 2022|Featured, Investor News, Medical, Press Releases|0 Comments

Jackson Center, PA, April 18, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease states.  The latest success was again extracorporeal elimination of E. coli bacteria from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro, in under 20 minutes.  This ...

Mar 8 2022

Halberd Expands Its Technical Expertise With the Addition of Microbiology Professor

By |2022-03-07T23:31:23-05:00March 8th, 2022|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 8, 2022 – Halberd Corporation (OTC-PINK: "HALB") is pleased to announce Youngstown State University’s (YSU) Dr. Chester R. Cooper has joined its technical team.  Dr. Cooper currently holds the position of Professor, Department of Biological Sciences, at Youngstown State University.  Dr. Cooper has been a valuable resource in Halberd’s work at ...

Jul 28 2021

Halberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept – “Never Before Accomplished”

By |2021-07-27T17:35:26-04:00July 28th, 2021|Featured, Investor News, News|0 Comments

A Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer’s Disease/PTSD/CTE Jackson Center, PA, July 28, 2021 – Halberd Corporation (OTC-PINK: "HALB") establishes “proof of concept” taking a major step towards the elimination of multiple infectious diseases, such as, malaria, tuberculosis, sepsis, meningitis, and pandemics, among others, by successfully eliminating ...

Jun 9 2021

Halberd Corporation Undertakes Process Toward the Elimination of Alzheimer’s Disease

By |2021-06-08T21:47:47-04:00June 9th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, June 9, 2021 – Halberd Corporation (OTC-PINK: "HALB") commences experimentations to eradicate three of the principal components of Alzheimer’s Disease.  By eliminating these three critical antigens, which form the basis for neurofibrillary tangles in the brain, Halberd believes that its patented extracorporeal treatment process can slow or stop the progress of the ...

May 25 2021

Halberd Corporation Successfully Conjugates Metallic Particles and E. Coli Antibody

By |2021-05-24T21:12:58-04:00May 25th, 2021|Featured, Investor News, News|0 Comments

Breakthrough Achievement Enables Extracorporeal Eradication of Pathogens Via Radio Frequency Waves and/or Laser Emissive Energy Jackson Center, PA, May 25, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with an available E.coli antibody.  This milestone is a result of the Halberd sponsored research being conducted at GreenBioAz by Dr. ...

Mar 30 2021

Halberd Corporation’s Scientific Breakthrough: Conjugating Metallic Particles to SARS-CoV-2 and E. Coli Antigens

By |2021-03-29T20:24:19-04:00March 30th, 2021|Featured, Investor News, News, Uncategorized|0 Comments

Paves Way for Disease Elimination by Radio Frequency Waves Jackson Center, PA, March 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated (joined) metallic nanoparticles with its patent-pending SARS-CoV-2 antibody, while still maintaining the antibody’s antigen-neutralizing properties.  This was a key scientific hurdle to overcome in implementing its patent-pending extracorporeal disease eradication methodology through ...

Go to Top